A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous) (HALO) First published 22/11/2022 Last updated 20/03/2026 EU PAS number:EUPAS49827 Study Ongoing